A compound-target pairs dataset: differences between drugs, clinical candidates and other bioactive compounds
Scientific Data · 21.10.2024 · 11 (1)
DOI: 10.1038/s41597-024-03582-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientific Data, online erschienen am 21.10.2024. Verfasst von A Lina Heinzke und 6 weiteren Autor:innen. Beteiligte Einrichtung: European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD, United Kingdom. Hauptthemen laut MEDLINE: Drug Discovery. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Wellcome Trust, European Molecular Biology Laboratory.
Abstract (Originalsprache)
Providing a better understanding of what makes a compound a successful drug candidate is crucial for reducing the high attrition rates in drug discovery. Analyses of the differences between active compounds, clinical candidates and drugs require high-quality datasets. However, most datasets of drug discovery programs are not openly available. This work introduces a dataset of compound-target pairs extracted from the open-source bioactivity database ChEMBL (release 32). Compound-target pairs in the dataset either have at least one measured activity or are part of the manually curated set of known interactions in ChEMBL. Known interactions between drugs or clinical candidates and targets are specifically annotated to facilitate analyses of differences between drugs, clinical candidates, and other active compounds. In total, the dataset comprises 614,594 compound-target pairs, 5,109 (3,932) of which are known interactions between drugs (clinical candidates) and targets. The extraction is performed in an automated manner and fully reproducible. We are providing not only the datasets but also the code to rerun the analyses with other ChEMBL releases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD, United Kingdom.
- Paul Leeson Consulting Ltd, Nuneaton, Warwickshire, CV13 6LZ, United Kingdom.
- Blue Burgundy Ltd, Ampthill, Bedfordshire, MK45 2AD, United Kingdom.
- Compound Management and Screening Center, Max-Planck-Institute of Molecular Physiology, Otto-Hahn-Str. 11, 44227, Dortmund, Germany.
- Department of Chemical Biology, Max-Planck-Institute of Molecular Physiology, Otto-Hahn-Straße 11, 44227, Dortmund, Germany.
- Faculty of Chemistry and Chemical Biology, Technical University Dortmund, Otto-Hahn-Straße 6, 44227, Dortmund, Germany.
ORCID-Profile: A Lina Heinzke, Barbara Zdrazil, Robert J Young, Andrew R Leach
Förderung
- Wellcome Trust
- European Molecular Biology Laboratory
Zitieren
APA
Heinzke, A. L., Zdrazil, B., Leeson, P. D., Young, R. J., Pahl, A., Waldmann, H., & Leach, A. R. (2024). A compound-target pairs dataset: differences between drugs, clinical candidates and other bioactive compounds. Scientific Data, 11(1). https://doi.org/10.1038/s41597-024-03582-9
Vancouver
Heinzke AL, Zdrazil B, Leeson PD, Young RJ, Pahl A, Waldmann H, et al. A compound-target pairs dataset: differences between drugs, clinical candidates and other bioactive compounds. Scientific Data. 2024;11(1). doi:10.1038/s41597-024-03582-9
BibTeX
@article{Heinzke2024,
author = {Heinzke, A Lina and Zdrazil, Barbara and Leeson, Paul D and Young, Robert J and Pahl, Axel and Waldmann, Herbert and Leach, Andrew R},
title = {A compound-target pairs dataset: differences between drugs, clinical candidates and other bioactive compounds},
journal = {Scientific Data},
year = {2024},
volume = {11},
number = {1},
doi = {10.1038/s41597-024-03582-9}
}
EUVIMED